Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25359611 | 1.00 | CNR1 (0.52) | CNR1CNR2ALDH1A1 | |
| SCHEMBL12187878 | 1.00 | CNR1 (0.52) | CNR1CNR2ALDH1A1 | |
| SCHEMBL15543930 | 1.00 | CNR1 (0.52) | CNR1CNR2ALDH1A1 | |
| SCHEMBL21235537 | 1.00 | CNR1 (0.52) | CNR1CNR2ALDH1A1 | |
| SCHEMBL12186948 | 0.96 | ALDH1A1 (0.47) | CNR1CNR2ALDH1A1 | |
| SCHEMBL12187705 | 0.96 | ALDH1A1 (0.46) | CNR1CNR2ALDH1A1 | |
| SCHEMBL2641916 | 0.96 | ALDH1A1 (0.46) | CNR1CNR2ALDH1A1 | |
| SCHEMBL14935335 | 0.96 | ALDH1A1 (0.46) | CNR1CNR2ALDH1A1 | |
| SCHEMBL22403747 | 0.96 | ALDH1A1 (0.56) | CNR1CNR2ALDH1A1 | |
| SCHEMBL23017054 | 0.96 | ALDH1A1 (0.56) | CNR1CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630985-B1 | SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS | ARCTURUS THERAPEUTICS INC (US) | 2025-08-27 | — | — | EP | disclosed |
| EP-3630964-B1 | THERAPEUTICS FOR GLYCOGEN STORAGE DISEASE TYPE III | ULTRAGENYX PHARMACEUTICAL INC (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2025024442-A1 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH BSEP DEFICIENCY | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| EP-4377331-A2 | MRNAS FOR TREATMENT OR PROPHYLAXIS OF LIVER DISEASES | CureVac SE (DE) | 2024-06-05 | — | — | EP | disclosed |
| EP-4376883-A2 | RNA VACCINES | Arcturus Therapeutics, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| EP-4352038-A2 | IONIZABLE CATIONIC LIPIDS FOR RNA DELIVERY | Arcturus Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4334455-A1 | LIPID COMPOSITIONS COMPRISING PEPTIDE-LIPID CONJUGATES | Arcturus Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4333898-A2 | PEPTIDE-LIPID CONJUGATES | Arcturus Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4297889-A1 | LIPID NANOPARTICLE (LNP) ENCAPSULATION OF MRNA PRODUCTS | Nature's Toolbox, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-4299750-A2 | COMPOSITIONS AND METHODS FOR TREATING ORNITHINE TRANSCARBAMYLASE DEFICIENCY | Arcturus Therapeutics, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2020191103-A1 | METHOD OF MAKING LIPID-ENCAPSULATED RNA NANOPARTICLES | ARCTURUS THERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| EP-3697912-A1 | NOVEL ARTIFICIAL NUCLEIC ACID MOLECULES | CureVac AG (DE) | 2020-08-26 | — | — | EP | disclosed |
| EP-3630200-A1 | THERAPEUTICS FOR PHENYLKETONURIA | Arcturus Therapeutics, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3630964-A1 | THERAPEUTICS FOR GLYCOGEN STORAGE DISEASE TYPE III | Ultragenyx Pharmaceutical Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3500295-A2 | RNA FOR CANCER THERAPY | CureVac AG (DE) | 2019-06-26 | — | — | EP | disclosed |
| WO-2019077001-A1 | NOVEL ARTIFICIAL NUCLEIC ACID MOLECULES | CUREVAC AG (DE) | 2019-04-25 | — | — | WO | disclosed |
| WO-2018222925-A1 | THERAPEUTICS FOR PHENYLKETONURIA | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| WO-2018222926-A1 | THERAPEUTICS FOR GLYCOGEN STORAGE DISEASE TYPE III | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| WO-2018104540-A1 | RNAS FOR WOUND HEALING | CUREVAC AG (DE) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018033254-A2 | RNA FOR CANCER THERAPY | CUREVAC AG (DE) | 2018-02-22 | — | — | WO | disclosed |